Compare FSK & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSK | SUPN |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 2008 | 2010 |
| Metric | FSK | SUPN |
|---|---|---|
| Price | $10.51 | $49.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $13.19 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 3.2M | 412.5K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 19.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | N/A | $22.70 |
| Revenue Next Year | N/A | $19.14 |
| P/E Ratio | $265.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.72 | $29.16 |
| 52 Week High | $22.68 | $59.68 |
| Indicator | FSK | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 45.58 |
| Support Level | $9.85 | $49.46 |
| Resistance Level | $10.56 | $52.26 |
| Average True Range (ATR) | 0.35 | 1.60 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 35.82 | 30.39 |
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.